On the last working day of 2017, Zhongren Kangbo (Tianjin) Biomedical Technology Center was formally signed and settled in Binhai - Zhongguancun Science Park. This enterprise that focuses on the research, development and application of Chinese and Western medicines, healthcare food, new resource food and special cosmetics will be the driving force for creating an innovative development cluster for the life and healthcare industry in Binhai New Area.
Looking back over the past year, there are many life and healthcare enterprises that have taken the development potential of Binhai New Area into consideration, or have come here to settle down or find opportunities for cooperation. In the past year, a group of innovative technologies and products with broad market prospects have been developed and launched in Binhai New Area, demonstrating the vitality of the industry. At the same time, Binhai New Area is also continuing to step out the pace of cooperation, build a platform for cooperation, promote technological innovation and escalate industries.
Corporate vitality bursts more achievements in innovation.
For a long time in the past, the bio-pharmaceutical companies in Binhai New Area have always assumed the mission of independent innovation of science and technology and absorption of advanced achievements. In the past year, many enterprises in Binhai New Area have entered the harvest period of achievements, constantly reselling Binhai New Area brands in the market in technology and products.
October 20, 2017, for Tianjin CanSino Biologics Inc. (CanSino), is a milestone in the development process of the day. On this morning, the State Food and Drug Administration announced that the first recombinant Ebola virus vaccine was approved for registration of new drugs. As one of the two joint R & D units of this innovative recombinant vaccine product with independent intellectual property rights and independent research and development in China, CanSino's team made tremendous efforts for the birth of this innovative achievement. On the very same afternoon, the first phase of CanSino Vaccine Industrialization Base was officially completed in the TEDA West, marking the completion of the first mass production of Ebola virus vaccine in Binhai New Area in 2017, becoming a remarkable part in the course of developing the life and healthcare industry in Binhai New Area in 2017.
Another pharmaceutical company called Dynamiker Biotechnology (Tianjin) Co., Ltd. also continues the rapid development trend as in 2017. The past year, Dynamiker biological Candida manna detection kit products successfully passed the audit by the State Food and Drug Administration, and successfully obtained three types of national medical device product registration cards. The successful registration of this kit provides more clinical testing tools for the diagnosis of invasive Candida infections. In the meantime, Dynamiker 's G test scientific research literature on Dynamiker 's biological products was successfully published in Medical Mycology in 2017, which indicates that Dynamiker's invasive and mycological early rapid diagnostic products are recognized in the UK and it has completed India's "Form 10" registration to the officially obtain the permit access to Indian market.
In addition, the 1.6 anti-tumor drug project called Doxycycline Hydrochloride Tablets, developed by the team of Tianjin International Joint Academy of Biomedical (TJAB for short) won the approval of clinical trials last year, marking that TJAB has achieved breakthrough ‘’in clinical research and development of new drugs independently. This new drug will hopefully become an affordable anticancer drug for the common people.
Binahi New Area will explore transformation and upgrading for companies to rely on regional cooperation.
At present, the domestic life and healthcare industry is in a critical period of seeking "strength" from "big size." With the wave of coordinated development of Beijing, Tianjin and Hebei sweeping over, all three parties are leveraging the giants of regional cooperation in shaping a sample of cooperation for industrial restructuring and upgrading. As a major gathering place for bio-pharmaceutical enterprises and research institutes in Tianjin, Binhai New Area focuses on the exploration of regional industrial cooperation, and in the past year, it has been accelerating the pace of regional cooperation.
Recently, the reporter learned that the clinical precision medical center jointly promoted by Binhai-Zhongguancun Science Park and Beijing-Tianjin authoritative medical institutions is expected to land in Binhai New Area. Hui Ru Tai, Former Vice President of Fuwai Hospital of Chinese Academy of Medical Sciences, Director of the State-level International Joint Research Center of the State Bureau of Science and Technology and Director of the National Key Laboratory of Cardiovascular Diseases, told reporters: "There are more large hospitals in Binhai New Area, and policies, in particular, the personnel policy is more flexible and it is close to Beijing, which is very suitable for the clinical transformation of precision medical centers."
Coordinated efforts not only come from Beijing, but also from Hebei, Gansu and other provinces. Recently, Tianjin International Joint Academy of Biomedical (TJAB for short) and Cangzhou Bohai New Area signed a cooperation agreement to make full use of its own advantages, to carry out technical research, project development and other in-depth cooperation with biomedical enterprises in Cangzhou Bohai New Area, to build a biomedical industry innovation alliance and to achieve win-win development. TJAB and Baiying City, Gansu Province will "join hands", and both sides will work together to dig deeper industrial cooperation, to strengthen exchanges and cooperation, and to promote accelerated landing of scientific and technological achievements.
It is not difficult to see from the above achievements and cooperation that the life and healthcare industry in Binhai New Area is releasing the signal of industrial upgrading. With the vigorous development of enterprises and the accelerated construction of platform carriers, the life and healthcare industry in Binhai New Area will also accelerate to a new level of high-end cluster and industrial development.
According to the relevant person in charge of the District Commission of Industry and Information, the life and healthcare industry has now become one of the eight new key industries in Binhai New Area. It will mainly undertake the manufacturing of artificial organs and implants, the manufacture of biological medicines, accelerate the creation of major new drugs and promote construction of the synthesis biotechnology innovation platform and other tasks. According to the plan, by 2020, the industrial system covering the entire life cycle will be basically completed in Binhai New Area with the output value of 100 billion yuan.